Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial overdiagnosis and overtreatment of clinically insignificant disease. Biparametric magnetic resonance imaging (bpMRI) has emerged as a promising imaging modality to improve the detection of clinically significant prostate cancer while reducing unnecessary biopsies. In this prospective follow-up study, men who previously participated in prostate cancer screening and had no evidence of malignancy at baseline will be invited to undergo repeat screening approximately five years later. The study aims to evaluate the longitudinal performance of repeat screening using PSA and MRI, determine the incidence of newly detected clinically significant prostate cancer after an initial negative screening, and assess changes in imaging and clinical findings over time. The results will provide evidence on the value and optimal interval of repeat prostate cancer screening in men with an initially negative evaluation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni, którzy świadomie wyrażają chęć do udziału w badaniu przesiewowym raka prostaty
- •Wcześniej nie wykonywano biopsji prostaty
- •Oczekiwana długość życia ponad 10 lat
- •Uczestnictwo w poprzedniej fazie badania VISIONING
✗ Disqualifies
- •Prostata większa niż 80 ml
- •Ostra infekcja dróg moczowych
- •Problemy z oddawaniem moczu - wyniki testów 19 lub więcej
- •Poważne objawy prostatyczne wymagające leczenia (wyniki testów 20 lub więcej)
- •Oczekiwana długość życia poniżej 10 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 50 Years
- Last updated (source)
- August 13, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
University Hospital Basel, Urology
Basel, Switzerland
Trial contact
Cyrill Rentsch, Prof.
Viktor Alargkof, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.